Note to users. If you're seeing this message, it means that your browser cannot find this page's style/presentation instructions -- or possibly that you are using a browser that does not support current Web standards. Find out more about why this message is appearing, and what you can do to make your experience of our site the best it can be.
AAAS Promotion

Site Tools

  • AAAS
  • Subscribe
  • Feedback

Site Search

Search Advanced

Science 28 June 1996:
Vol. 272. no. 5270, pp. 1888 - 0
DOI: 10.1126/science.272.5270.1888
Prev | Table of Contents | Next

Perspective

Barry R. Bloom

To many people it is unfathomable that after more than 10 years of research, there is no human immunodeficiency virus (HIV) vaccine ready for large-scale efficacy trials. A complex web of scientific, political, and social issues remains to be untangled. Barry Bloom (Howard Hughes Medical Institute, Albert Einstein College of Medicine, USA) takes a hard look at the fundamental questions that must be answered before a vaccine against acquired immunodeficiency syndrome (AIDS) becomes a reality.

The author is in the Howard Hughes Medical Institute, Department of Microbiology, Albert Einstein College of Medicine, Bronx, NY 10461, USA.

Volume 272, Number 5270, Issue of 28 June 1996, pp. 1888-1890
©1996 by The American Association for the Advancement of Science.

Read the Full Text


THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES:
Retaining Hard-to-Reach Women in HIV Prevention and Vaccine Trials: Project ACHIEVE.
P. Brown-Peterside, E. Rivera, D. Lucy, I. Slaughter, L. Ren, M. A. Chiasson, and B. A. Koblin (2001)
Am J Public Health 91, 1377-1379
   Abstract »    Full Text »    PDF »
Evidence for Viral Virulence as a Predominant Factor Limiting Human Immunodeficiency Virus Vaccine Efficacy.
P. Mooij, W. M. J. M. Bogers, H. Oostermeijer, W. Koornstra, P. J. F. Ten Haaft, B. E. Verstrepen, G. Van Der Auwera, and J. L. Heeney (2000)
J. Virol. 74, 4017-4027
   Abstract »    Full Text »
beta -Chemokines and neutralizing antibody titers correlate with sterilizing immunity generated in HIV-1 vaccinated macaques.
J. L. Heeney, V. J. P. Teeuwsen, M. van Gils, W. M. J. M. Bogers, C. D. G. Morghen, A. Radaelli, S. Barnett, B. Morein, L. Akerblom, Y. Wang, et al. (1998)
PNAS 95, 10803-10808
   Abstract »    Full Text »    PDF »
Kinetics of Antiviral Activity by Human Immunodeficiency Virus Type 1-Specific Cytotoxic T Lymphocytes (CTL) and Rapid Selection of CTL Escape Virus In Vitro.
C. A. Van Baalen, M. Schutten, R. C. Huisman, P. H. M. Boers, R. A. Gruters, and A. D. M. E. Osterhaus (1998)
J. Virol. 72, 6851-6857
   Abstract »    Full Text »    PDF »


ADVERTISEMENT
Click Me!

ADVERTISEMENT
Click Me!

To Advertise     Find Products